Unilateral Papilledema as a Rare Manifestation of Cerebral Neurotoxoplasmosis in HIV Patient: Case Report

A.A. Mas Putrawati Triningrat1*, Ni Luh Made Novi Ratnasari1, Made Paramita Wijayati1, Ida Ayu Sri Indrayani2, I Made Agus Kusumadjaja1 and Ariesanti Tri Handayani1

1Opthalmology Department, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Hospital, Denpasar.
2Neurology Department, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Hospital, Denpasar.
*Corresponding Author E-mail: masputra06@gmail.com

https://dx.doi.org/10.13005/bpj/2581

(Received: 30 August 2022; accepted: 10 November 2022)

Cerebral toxoplasmosis is one of the opportunistic diseases that present in patients with HIV/AIDS. One of the rare symptoms is unilateral papilledema due to cerebral toxoplasmosis. A 26-year-old male patient came with complaints blurred vision for 2 months. The patient had a history of pouting lips, and weakness face, arm, and legs on the left side of the body. The patient has been diagnosed with the observation of space occupying lesion Cerebri in November 2020. Patient with HIV stage IV (WHO) infection and CD4 14 cells/uL and viral load 5.43 x 10^5 copies/mL. Visual acuity left eye 6/18 PH 6/12, contrast sensitivity examination in both eyes 1.65, and the results of FD-15 are within normal limits, but the results of perimetry was enlargement of blind spot, relative afferent pupillary defect in the left eye, with optic nerve head swelling in the left eye. An MRI showed the presence of intracerebral neurotoxoplasmosis. Papilledema is the manifestation of optic nerve abnormality due to an increase in intracranial pressure. Cerebral toxoplasmosis leads to asymmetric target lesion present with ring enhancement image on MRI with contrast which causes SOL and manifests as papilledema. Bilateral papilledema is a hallmark of increasing cerebrospinal fluid pressure, but unilateral papilledema is a rare case with a 2% of prevalence among papilledema cases. Two proposed mechanisms of atypical papilledema were anatomical nerve sheath anomalies and unilateral axoplasmic blockage of the lamina cribrosa. Early diagnosis and appropriate treatment have a very important role in determining the prognosis of patients with cerebral toxoplasmosis.

Keywords: Cerebral Toxoplasmosis; HIV/AIDS; Unilateral Papilledema.

Human Immunodeficiency Virus (HIV) is a type of retrovirus that infects the immune system through the destruction of CD4 lymphocyte cells and develops into acquired immunodeficiency syndrome (AIDS). According to the United Nations Program on HIV and AIDS (UNAIDS) in 2019, the prevalence of HIV in Southeast Asia is 3.8 million people/year, equivalent to 78% of the total infection cases. The prevalence in Indonesia shows that in 2019 there were 50,828 HIV cases, and Bali Province was in the 7th position with the highest number of HIV/AIDS cases.1 HIV patients are also often accompanied by opportunistic infections, one of which is cerebral toxoplasmosis with an incidence ranging from 35 to 80% of the total HIV cases.2
**Toxoplasma gondii** infection in humans can occur through the oral route, transplacental, blood transfusion, and through organ transplantation.1,2 *Toxoplasma gondii* in the form of tachyzoites can enter via the oral route to the reticuloendothelial system (RES). In the digestive tract, the cyst wall will be damaged by digestive enzymes and will release sporozoites. After from the intestine, the parasite will enter the systemic circulation and spread to various organs, especially the lymph, skeletal, central nervous system, placenta and retina.3,4

The manifestations of cerebral toxoplasmosis depend on the location and number of lesions. Damage to the CNS will give a typical picture in the form of multiple lesions with extensive necrotic area on radiology, as well as clinical symptoms such as headache (49-63%), fever (41-68%), focal deficits (22-80%), seizures (19-29%), confusion (15-52%), ataxia (15-25%), lethargy (12-44%), cranial nerve weakness (12-19%), and visual disturbances (8-15%).5

The most common ocular symptoms of toxoplasmosis are blurred vision and decreased visual acuity, ocular pain, floaters, and photophobia may be present in some cases. HIV was found positive in tear, corneal, vitreous, and chorioretinal tissue samples with affected ocular structures including adnexa, anterior segment, posterior segment, and neuro-ophthalmic. Neuro-ophthalmic manifestations occurring in 10% to 15% of HIV patients include papilledema, cranial nerve palsy, ocular motility disorders, and visual field defects.6

In immunocompetent patients, an activated immune reaction is able to envelop the tachyzoites into a dormant cyst form. However, in patients with immunocompromised conditions, a disordered immune system will cause more severe clinical symptoms, both in acute infection and due to reactivation of dormant cysts.3,4

Papilledema is the most common neuro-ophthalmic manifestation in optic nerve head caused by increasing intracranial pressure (ICP). Papilledema due to cerebral toxoplasmosis occurs due to the connection of the subarachnoid cavity in the brain with the optic nerve membrane. If there is an infection that causes an increase in ICP, this increase will be transmitted to the optic nerve so that there is a disturbance in axoplasmic transport.3,7 Optic disc edema usually manifests as hyperemia, dilatation, a gray appearance around the optic nerve, and telangiectasia of the disc surface capillaries. This also results in the appearance of flame hemorrhages around the disc. When disc edema and visual impairment are present, the differential diagnosis should include anterior ischemic optic neuropathy (AION), papillitis, intraorbital compression, infection and CNS lesions.8

**Case description**

A 26-year-old male patient came to the Prof. Dr. IGNG Ngoerah Hospital on January 29, 2021, with complaints of blurred vision in his left eye for two months ago. The patient said the blurring occurred suddenly and persisted until now. Complaints of pain when glancing (-), severe pain in the eye denied, intermittent headaches denied, history of nausea (-) vomiting (-). Other complaints such as red eyes (+), watery (+), and eye discharge (+) in the last 4 days ago. Foreign body sensation (+), stinging (+), yellowish white, and sticky eye discharge comes out in the morning. The patient felt difficulty to open his eyes in the morning due to the discharge.

Patient has history of weakness in half of the body (+), pouting lips, and slurred speech for 2 months ago. Earlier, the patient was said to be able to stand on his own, but later when he was riding a motorcycle, the patient fell due to weakness in the left half of his body. The patient was treated in the Wijaya Kusuma Room at Sanglah Hospital with obs Space occupying lesion (SOL) cerebral et causa suspect cerebral abscess dd tumor dd vascular process in November 2020. While being treated the patient received Ultravist therapy 1 x 1 (IV), Acetylcysteine 3 x 200 mg, Pyrimethamine 1 x 25 mg, Clindamycin 1 x 150 mg, Dexamethasone 4 x 10 mg (I.V), Omeprazole 2 x 40 mg (I.V), Paracetamol 3 x 1000 mg (I.O), Micafungin 1 x 50 mg (IV). During the treatment, the patient admitted that his left eyelid could not close completely during sleep. After that, the patient’s left eye began to watery and discharge dirt, and the patient just realized that the left eye (LE) was blurrier than the right eye (RE).

History of chronic diseases such as diabetes mellitus and hypertension were denied. History of being diagnosed with HIV 3 months ago (+) with CD4: 14 cells/mm3 and viral load 5.43 x 105 copies/mL (30 November 2021). After being...
diagnosed, the patient received treatment with Highly Active Antiretroviral Therapy (HAART): Fix drugs combination (FDC) 1 x 1 consisting of Lamivudine 150 mg, Tenofovir 300 mg, and Efavirenz 600 mg. The patient has also been diagnosed with condyloma acuminata and treated with 80% Trichloracetic acid (TCA) solution every week and 20 mg zinc tablets every 4.5 hours. The patient has a history of changing partners before being diagnosed with HIV stage IV. Denied history of using drugs, history of glasses (-), eye surgery (-), allergies (-), and history of suffering from COVID-19 was denied.

On January 29, 2021, the patient came to the ophthalmology polyclinic and on ophthalmology physical examination, it was obtained vision OS 6/18 pinhole (PH) 6/12 while vision OD 6/12 PH 6/6. The intraocular pressure of the patient’s eye was found to be within normal limits of OD 16 mmHg and OS 12 mmHg. Examination of the anterior segment of the eye found positive conjunctival vascular injection (CVI) in both eyes, secret (+), positive direct pupillary reflex in both eyes, positive indirect pupillary reflex in both eyes, and positive Rapid Afferent Pupillary Defect (RAPD) in both eyes. Funduscopy OS papillary nerve II is round, blurred, cup disc ratio (CDR) is difficult to evaluate, arterial to the venous

Fig. 1. (A) Humphrey Visual Field test on 1/2/2021 showed an enlarged blind spot in the left eye; (B) Humphrey Visual Field test on 16/2/2021 showed that there was still a significant enlargement of the blind spot in the left eye.
ratio (aa/vv) is 2/3, the retina is good, and macular reflex is positive. Meanwhile, funduscropy of OD eye revealed well-defined round nerve papillae, hyperemia, CDR 0.3, aa/vv 2/3 good retina, and positive macular reflex.

The dry eye examination, namely Schirmer I, obtained 7 mm in the right eye and 9 mm in the left eye, examination of tears breaks up time (TBUT) in the right eye for 4 seconds and the left eye for 6 seconds. Contrast sensitivity examination in both eyes did not find a decrease in contrast sensitivity (ODS 1.65), Ishihara in both eyes could see as many as 25 plates well, and the results of the Farnsworth D-15 test (FD-15) were within normal limits. The examination was then followed by evaluation of the posterior segment, Humfrey Visual Field (HVF) test, and Optical Coherent Tomography (OCT).

The posterior segment of the patient’s left eye showed round nervus II papillae, blurred boundaries, difficult to evaluate Cup Disc Ratio (CDR), bulging (+), good retina, good macular reflex (+). The results of the HVF examination revealed an enlargement of the blind spot in the patient’s left eye (Figure 1). OCT results of the left eye papillary nerve layer showed swelling in all quadrants of the left eye (Figure 2).

Laboratory investigations showed non-reactive anti-toxo IgM: 0.09 IU/mL, Anti-toxo reactive IgG > 300 IU/mL, LED 53.9 mm/hour.

Fig. 2. (A) Fundus photo on 1/2/2021 showing well-defined rounded OD of papillary nerve II, CDR 0.3, a/v 2/3 retina good, RM (+) and Papilledema in OS with round Papil N II blurred boundaries, bulging (+), CDR sde, good retina, RM (+); (B) Fundus photo on 16/2/2021 shows relatively the same condition with OD Papil N II with firm boundaries and OS Papil Edema (Courtesy of Novi, 2021)
Magnetic Resonance Imaging of the head on February 4, 2021, and based on the results of MRI of the orbital focus, a ring enhancement image was obtained which suggested neurotoxoplasmosis in the gray and white matter of bilateral fronto-parieto-temporal lobes, bilateral basal ganglia, bilateral thalamus, bilateral caudate nucleus, right-sided midbrain, bilateral pons and cerebellar hemispheres; left sphenoid dilatant pneumosinus extending to the left orbital apex that appears to cause mild compression of the left optic nerve sheath; Bilateral oculi, bilateral optic nerves, and bilateral extraocular muscles showed no abnormalities; Bilateral maxillary, sphenoid and left ethmoid sinusitis; deviation of the nasal septum to the left (Figure 3).

The patient returned for control on February 16, 2021, and after the results of the head MRI was obtained, the patient was decided for

Fig. 3. Magnetic Resonance Imaging (MRI) of orbital focal head (A, B) Axial head MRI showing multiple ring enhancement images in bilateral gray and white matter basal ganglia, bilateral thalamus (red arrows); (C) Coronal MRI section showing ring enhancement oval (red arrow) in the left basal ganglia and midbrain. (D) Extension of the left sphenoid dilatans pneumosinus to the orbital apex compresses the optic canal (red circle)
Fig. 4. (A) Humphrey Visual Field test on 19/4/2021 showed that there was still an enlargement of the blind spot in the left eye; (B) The Humphrey Visual Field test on 16/6/2021 showed that there was no enlargement of the blind spot in the left eye.

Fig. 5. Fundus photo on 16/6/2021 shows a well-defined optic nerve papilla in the left eye. (Courtesy of Novi, 2021)
observation, the control returned to the neurology and internal polyclinic for the management of cerebral neurotoxoplasmosis, and was controlled every 2 months to monitor the development of visual acuity, color, contrast sensitivity, and the patient’s field of view. Neurology colleagues gave therapy with Pyrimethamine 2 x 25 mg and Clindamycin 4 x 300 mg (tapering off).

The next follow-up on April 19, 2021, the patient’s visual function was re-evaluated comprehensively. The patient showed significant improvement in visual acuity and could be corrected. OD vision was 6/9 PH 6/6 (S-0.50 6/6), OS 6/9 PH 6/6 (S-0.50 6/6).

ODS contrast sensitivity of 1.65, evaluation of color vision with Ishihara obtained ODS 25 plates, FD-15 ODS within normal limits, the anterior segment of ODS did not find any ocular signs of toxoplasmosis. Evaluation of the posterior segment found clear ODS vitreous, right eye fundus showing well-defined round N II papillae, CDR 0.3, aa/vv 2/3 retina good, RM (+). Meanwhile, for the fundus OS, the papillary N II was still round with blurred boundaries, hyperemia, low CDR, good retina, and RM (+). No active lesions or Toxoplasma scars were found in the retina of the right and left eyes. Evaluation of the visual field with HFV found that there was still an enlargement of the blind spot in the left eye which in subsequent controls got better (Figure 4).

The patient continued his treatment at the Neurology polyclinic and VCT for neurotoxoplasmosis and HIV therapy. Treatment from the neurologist was continued with Pyrimethamine 1 x 25 mg, Clindamycin 2 x 300 mg, and Mecobalamin 3 x 500 mg with consideration of clinical and neurological improvement in the patient. Antiretroviral therapy from VCT was continued with the formulation of fixed drugs formula 1 x 1 (Tenofovir 300 mg + Lamivudine 150 mg + Efavirenz 600 mg) and prophylaxis with Cotrimoxazole 1 x 960 mg. CD4 and clinical monitoring continued during subsequent follow-ups.

Improvements in visual acuity, visual field, and posterior segment were increasingly shown by the patient at the time of the next follow-up on June 16, 2021. OD vision was obtained OD was 6/9 PH 6/6 (S-0.50 6/6), the vision was OS 6/9 PH 6/6 (S-0.50 6/6). Contrast sensitivity of ODS was 1.65, evaluation of color vision with Ishihara obtained ODS 25 plates, FD-15 ODS within normal limits, anterior segment ODS within normal limits, fundus OD papillary N II rounded with clear margins CDR0.3, aa/vv 2/3 retina good, macula RM (+) as well as on funduscopy OS where papill N II is well demarcated with CDR that can be assessed. Evaluation using fundus photos, HVF is also still being done to evaluate the patient’s visual function.

Laboratory examination on the patient showed CD4: 121.2 cells/µL, CD8: 1,721.4 cell/µL, HIV viral load: undetectable per mL of blood. Patients were planned for observation from the ophthalmology clinic and continued treatment at VCT and Neurology Poly for tapering off clindamycin and pyrimethamine.

**DISCUSSION**

Papilledema is one of the manifestations of various spectrum diseases of the optic nerve, including anterior ischemic optic neuropathy, non-arteritic ischemic optic neuropathy, and neoplasms (meningioma, optic nerve glioma). Ischemic neuropathy and optic neuritis are the most common differential diagnoses of unilateral papilledema in young adults <50 years of age.

This case reports a fairly rare manifestation of unilateral papilledema in a 26-year-old male patient with a history of HIV/AIDS. A decrease in the patient’s visual acuity and visual field is one of the manifestations of an increase in intracranial pressure (ICP) due to intracerebral Toxoplasmosis infection.

The most common manifestation of Toxoplasmosis in the eye is toxoplasma chorioretinitis, while optic neuritis due to toxoplasma without retinitis is quite rare. *Toxoplasma gondii* is an obligate intracellular parasite that is widely distributed throughout the world. In Indonesia, the prevalence of *T. gondii* seropositive in humans ranges from 2% to 63%. This parasite causes asymptomatic persistent chronic infection in immunocompetent individuals, but in immunocompromised individuals, reactivation will occur, causing clinical symptoms.

Cerebral toxoplasmosis is an opportunistic infection of the central nervous system that is most often found in HIV/AIDS patients, especially...
in HIV/AIDS patients with low CD4 cells. In patients with HIV infection, *Toxoplasma gondii* causes severe opportunistic infections that require appropriate management.5,9

A study by Anuradha and Preethi in India showed that the seropositive T. gondii among HIV patients was 34.78%.9 This study is also supported by Meisher et al., which showed that 67.8% of clinical manifestations of toxoplasmosis occurred in patients with HIV/AIDS compared to 30.9% of immunocompetent persons.10

The presence of toxoplasma infection in the central nervous system (CNS) produces multifocal lesions with a predilection for sites in the basal ganglia, frontal, parietal, and occipital lobes. Patients generally will complain of headaches, the appearance of focal neurologic deficits, seizures, changes in mental status, and fever. While the clinical symptoms of neuroophthalmology usually appear to include homonymous hemianopsia, quadranopsia, and muscle paresis of eye movements.11

Physiologically, the optic nerve originates from the ganlion cell layer on the retinal surface to the optic chiasm. The optic nerve consists of axons of retinal ganlion cells and glial cells. The number of axons tends to be fixed, while the number of glial cells and myelin is relatively variable in various places compared to axons. Anatomically, the optic nerve is divided into four parts:12

1) The intraocular region (optic nerve head) is about 1.0 - 1.02 mm long with a transverse diameter of 1.5 mm to the sclera. The optic nerve fibers in the optic disc are divided into four layers: the superficial nerve fiber layer, the prelaminar area, the laminar area, and the retro laminar area.

2) The intraorbital region starts from the posterior surface of the sclera and has a length of about 30-40 mm and a diameter of 3 mm due to the addition of the myelin sheath starting from the retro laminar. Intraorbita region nerve fibers are the longest part of the entire optic nerve, with a slightly tortuous shape like the letter “S”. About 8-15 mm behind the eyeball, the central retinal artery penetrates into the optic nerve.

3) Intracanalicular region is the region of the optic nerve in the optic canal which is part of the alla minor (lesser wing) of the sphenoid bone. Has a length of about 8 - 10 mm and is tightly fixed in the optic canal.

4) Intracranial region, the optic nerve leaves the optic canal at a distance of 1 mm in the medial cranial fossa as the optic nerve in the intracranial region. The length of the intracranial optic nerve fibers is ±10-16 mm. The nerve fibers of this region run superior to the ophthalmic artery and superomedial to the internal carotid artery. Because it is part of the CNS, the interorbital portion of

---

Fig. 6. Classification of the degree of papilledema according to the modified Frisen scale.11
the optic nerve is also covered by the pia mater, arachnoid, and dura mater.

The intracanalicular region of the optic nerve is the region most susceptible to trauma due to impact or compression due to anatomical abnormalities of the bones that make up the orbit. The optic canal is a canal composed of the ala minor (lesser wing) of the sphenoid bone and optic nerve, along with the ophthalmic artery running through this canal. The dilatation of the sphenoid sinus will cause pressure on the intracanalicular region of the optic nerve.\textsuperscript{12}

Papilledema is the most common neuro-ophthalmic manifestation in optic nerve disorders that occur in the optic nerve head due to increased ICP. Papilledema that occurs bilaterally is a typical sign of increased intracranial pressure either due to the effect of space pressure or increased cerebrospinal fluid (CSF). Unilateral papilledema is a rare condition. According to Chang et al. (2017), the prevalence of true unilateral papilledema is only around 2\% of all papilledema cases, with the highest cause due to malignancy or idiopathic intracranial hypertension (IIH).\textsuperscript{13}

Two hypotheses of the mechanism of developing unilateral papilledema are 1) The presence of abnormalities of the optic nerve sheath, either congenital or acquired, which results in inhibition of the transmission of increased intracranial pressure to the optic nerve; 2) Abnormalities in the venous sinuses and differential unilateral axoplasmic block that decrease the transmission of increased intracranial pressure to the scleral canal of the optic nerve.\textsuperscript{13,14}

The degree of papilledema based on the American Academy of Ophthalmology (2019) is divided according to the Frisen classification into five grades. Grade 0 optical disk normal, CDR normal; grade I blurring of the optic disc margin, the indistinct border with a grayish halo around it, grade II increased nasal border of the optic disc, blurring of the entire temporal margin with a 360° gray halo, grade III increased temporal border of the optic disc, obscurations of the optic disc major vessels, finger-like extensions radiating from the halo; grade IV elevation of the entire ONH margin, flat appearance without cup concavity, total obscuration of central retinal arteries and veins; grade V dome-shaped protrusion from ONH.\textsuperscript{11}

A typical feature of cerebral toxoplasmosis is the presence of an asymmetric target sign.\textsuperscript{15} In this patient, papilledema resulted from multiple ring enhancement lesions in bilateral fronto-parieto-temporal lobes, bilateral basal ganglia, bilateral thalamus, and bilateral caudate nuclei, causing bilateral perifocal edema and causing space-occupying effects in the brain parenchyma. This causes an increase in intracranial pressure, which is transmitted to the optic nerve via CSF flow in the subarachnoid space which is also connected to the sheath with the optic nerve.

The optic nerve in the intracanalicular region is the most crucial location for obstruction of CSF flow in the subarachnoid space of the optic nerve, which can cause a “bottleneck effect” on the opening of the optic canal in the intraorbita region, which is smaller in some cases than in normal people. The dura mater of the optic canal fuses with the periosteum of Os. The sphenoid produces a static portion. In contrast, the more dynamic part covers the pia mater and arachnoid layers.\textsuperscript{16}

In this patient, unilateral papilledema in the left eye was caused by the presence of perifocal edema of the mesencephalon and basal ganglia, which caused intracranial space-occupying effects and increased intracranial pressure. The increase in intracranial pressure will be transmitted through the CSF flow in the optic nerve subarachnoid space. A left sphenoid dilatation pneumosinus in this patient gave compression to the left intraorbital region. The opening of the left intraorbital optic canal is smaller than the lumens of the other optic canals. This results in a “bottleneck effect” on CSF flow in the subarachnoid space of the left optic nerve and results in the manifestation of grade III Frisen’s papilledema in the left optic disc.

Unilateral papilledema in this patient is an early manifestation of increased intracranial pressure due to cerebral neurotoxoplasmosis. If not treated properly will cause bilateral asymmetric papilledema in conditions of advanced intracranial pressure elevation. Sinus venous abnormalities due to left sphenoid dilatation pneumosinus also cause axoplasmic stasis to the optic nerve scleral canal and contribute to the development of left papilledema.

The management of this patient follows the treatment of toxoplasma cerebri from the neurology section and the procedure for treating
toxoplasmosis in the 2019 National Guidelines for Medical Services in HIV/AIDS patients. This patient was first identified with a CD4 count of 14 cells/μL. CD4 count < 200 cells/μL in HIV/AIDS patients increases the risk of developing CNS neurotoxoplasmosis due to reactivation of chronic infections. The management of cerebral toxoplasmosis is still using a combination of pyrimethamine loading dose 1 x 200 mg and clindamycin 4 x 600 mg. After administering the combination of the two antimicrobials, the evaluation will be carried out two weeks after the administration of clindamycin and pyrimethamine. Both neurological clinical evaluation and CT scan were carried out to monitor disease progression. Tapering off the dose of clindamycin and pyrimethamine was carried out based on clinical neurological monitoring in stages.

The 2019 National Guidelines for Medical Services in HIV/AIDS patients also recommends prophylaxis with Co-trimoxazole 1 x 960 mg in HIV/AIDS patients with CD4 < 100 cells/μL. Antiretroviral therapy can be started 2-3 weeks after diagnosis. This patient has received therapy according to PNPK with ARV FDC 1 x 1 and cotrimoxazole prophylaxis. Prophylactic administration can be discontinued in adult patients who have received ARVs and CD4 cells > 200 cells/μL for three consecutive months. Clindamycin and pyrimethamine can be given up to 6 months after ARV administration.

Management of unilateral papilledema in this patient was carried out with close observation for the first one month, followed by periodic observations every two months to show functional and anatomical improvement. In the 4th month, the patient had shown a significant improvement in visual acuity to 6/9 PH 6/6 ODS, improved contrast sensitivity, and HVF in the left eye, which no longer showed an enlargement of the blind spot. The anatomical improvement shown was evident by the reduction of papilledema in the second papillary N II of the left eye, the assessed CDR and the disappearance of papillary hyperemia in the 4th month of follow-up.

The clinical improvement in the ophthalmology department will provide input for the neurology department in seeking clinical improvement and periodic tapering off of Toxoplasmosis therapy. The management of cases of papilledema due to Toxoplasmosis cerebri requires multidisciplinary collaboration from the Neuro-ophthalmology, Neurology, and Tropical Infections Department to maximize the therapeutic outcome for the patient.

**CONCLUSION**

Cerebral toxoplasmosis is one of the opportunistic infections that occur in patients with HIV/AIDS. The manifestations of increased intracranial pressure can be in the form of bilateral or unilateral papilledema. Papilledema of the optic nerve indicates axoplasmic stasis caused by increased intracranial pressure. Appropriate and immediate treatment is needed to prevent chronic papilledema and papilledema to avoid permanent complications. Appropriate multidisciplinary diagnosis and management will prevent permanent optic nerve complications, which will determine the patient’s prognosis for both intracerebral improvement and vision and visual field.

**ACKNOWLEDGEMENT**

The authors would like to thank Udayana University, Sanglah General Hospital, and the patients which has helped a lot during this research.

**Author Contribution**

All authors have equal contributions in the manuscript.

**Conflict of Interest**

The authors declare no conflict of interest.

**REFERENCES**